Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

Antonio Tito Fojo; Alfred I Neugut

doi:10.1093/oncolo/oyad203

Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values

Oncologist. 2024 Feb 2;29(2):102-105. doi: 10.1093/oncolo/oyad203.

Authors

Antonio Tito Fojo¹, Alfred I Neugut¹

Affiliation

¹ Department of Medicine, Division of Hematology Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.

Abstract

This article continues the discussion on the results of the BILCAP trial and advocates for careful examination and consideration of data in its entirety to inform a clinician’s decision.

Publication types

Editorial
Comment

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use
Biliary Tract Neoplasms* / drug therapy
Capecitabine / therapeutic use
Humans

Substances

Capecitabine
Antimetabolites, Antineoplastic